Podcasts about diagnostics

Traditional MRIs often miss the real causes of neck pain because scans are taken while patients are lying down—not how they live or move every day. This new technology can reveal hidden issues like stenosis and radiculopathy that only show up when you're upright and in motion.Episode Notes: Weight-bearing MRI of the cervical spine: A scoping review of clinical utility and emerging applicationsLeander Tables- Save $1,000 on the Series 950 Table using the code EBC2025 — their most advanced flexion-distraction tablePatient Pilot by The Smart Chiropractor is the fastest, easiest to generate weekly patient reactivations on autopilot…without spending any money on advertising. Click here to schedule a call with our team.Our members use research to GROW their practice. Are you interested in increasing your referrals? Discover the best chiropractic marketing you aren't currently using right here!

Our guest, Hunter Ziesing shares his work with AI in assisting individuals in their quest for health and longevity.   Hunter spent the bulk of his career in investment banking focusing on the Healthcare, Consumer, and Technology areas. He was the founder of Charity of Choice, a non-profit focused on cancer research and health prevention. Early Overall Outcomes Biomarker Improvements A majority of patients showed significant movement in at least one critical biomarker (ApoB, VAT, bone density, VO2Max, HbA1c). ~80% improved at least one key biomarker. Common improvements included reductions in ApoB, decreases in visceral fat (VAT), and gains in lean mass/bone density. Major Findings from Diagnostics ~65% of patients had at least one significant finding from testing (e.g., early CAD on Cleerly, sleep apnea, insulin resistance, GI imbalances). These findings directly shaped interventions and escalations in care. Symptom Reversals ~30% experienced meaningful reversal of previously severe symptoms (e.g., hypertension control, prediabetes reversal, improved sleep apnea, reduction in chronic GI symptoms). Resources: ai.longevityhealth.me Our Sponsor: Haven Medical maker of the Cox 8 Table  

This episode explores how signs like changesin activity, weight, coat condition, and subtle health issues are often mistaken for normal aging in pets. Stacey Newton advises veterinarians and pet owners to look beyond these common signs and consider early diagnostics and assessments. She discusses how tools like Nationwide Laboratories Ageing Pet Diagnostics Resource Hub and the BSAVAPetSavers Ageing Canine Toolkit (ACT) can aid in identifying underlying health conditions early, enabling more targeted interventions andhelping pets live longer, healthier lives. A must-listen for anyone committed to improving senior pet care. Thank you to Nationwide Laboratories for making this episode possible.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss recent news about drug-resistant infections. Later, Paul Jannetto, Ph.D., director of the Clinical and Forensic Toxicology Lab, Clinical Mass Spectrometry Lab, and Metals Lab, joins Dr. Pritt for the deep dive segment. Together, they explore how diagnostics are shaping the future of therapeutics.  New podcast format launch (00:25): Drs. Morice and Pritt introduce the exciting new format for “Answers From the Lab,” including the addition of in-depth expert segments.   Drug-resistant infections (02:05): Discover how clinical diagnostics play a critical role in combating the growing threat of antibiotic resistance. Diagnostics' role in advancing precision medicine (13:28): Learn how diagnostics, specifically drug monitoring, are advancing personalized therapies and contributing to better outcomes. Note: Information in this post was accurate at the time of its posting. Resources Therapeutics testing: A clear path to accurate answers Therapeutics testing at Mayo Clinic Laboratories WHO warns of widespread resistance to common antibiotics worldwide Tests for infectious disease detection and identification  Connect with Us Is there a question or topic you'd like us to explore in a future episode? Email us at mayocliniclabs@mayo.edu. Learn more about our hosts and guests and connect with them on social media.  Bobbi Pritt, M.D.  Bio  |  LinkedIn Bill Morice, M.D., Ph.D. Bio  |  LinkedIn Paul Jannetto, Ph.D. Bio  |  LinkedIn

Early detection saves lives, but today's tools are often invasive, slow, or used too late. In this episode, Breath Diagnostics CEO Ivan Lo explains how a non-invasive breath test can detect volatile organic compounds (VOCs) associated with disease—positioning breath as a first-line screen for early-stage lung cancer and potentially pneumonia and TB. We cover the science (why breath can capture near real-time biological change), sensitivity/specificity signals from 800+ patients, and a go-to-market/regulatory plan that prioritizes post-op pneumonia (shorter trials, no entrenched standard of care) before lung cancer screening. We also discuss platform economics (low-cost disposables, existing LC-MS infrastructure), trial scale and cost, and how breath could support ongoing monitoring after treatment. Investors get a clear view of timelines, risks, and upside; founders get lessons on platform positioning, capital efficiency, and sequencing indications. Highlights include...Why breath (VOCs) can surface disease signals minutes–hours after biological changeFirst-line screening thesis vs. liquid biopsy and CT workflowsEarly data: ~94% sensitivity / 85% specificity across 800+ patients (lung cancer context)Regulatory path: post-op pneumonia first (faster FDA route), lung cancer nextUnit economics: low-cost cartridge + existing LC-MS labs (hub-and-spoke)Clinical design: trial scale, costs, and companion-diagnostic “cocktail” potentialPlatform beyond oncology: pneumonia, TB, inflammation, RUO for pharmaChapters00:00 Intro & why early detection needs a rethink00:47 What Breath Diagnostics does (the “breath bag”)03:34 VOCs 101: why breath can be earlier than blood06:41 First-line screen vs. confirmatory tests08:19 Will this be ubiquitous at annual visits?11:53 Commercialization path & funding realities12:37 Pneumonia first: faster FDA route14:09 Lung cancer timeline & business model15:34 Hospital economics & pneumonia savings18:24 Trial scale/costs; disposable chip economics20:34 Team, funding strategy, and sequencing22:08 Early data and a “false negative” biopsy case24:12 TAM & eligibility (20M Americans qualify)25:06 What success looks like (2–3 years)27:00 Investor closing thoughts

Jari Närhi, Co-Founder and CEO of NADMED, a University of Helsinki spin-out revolutionising how we understand and monitor NAD levels. With a background in mechanical engineering and a career spanning medtech, diagnostics and hospital operations, Jari brings a unique systems-level view on cellular health and innovation in clinical testing.In this episode, we explore why NAD (nicotinamide adenine dinucleotide) is so vital for human health, from fuelling ATP production to supporting DNA repair and immune regulation. Jari breaks down the science of NAD+, NADH and glutathione and why traditional lab methods like mass spectrometry have long failed to make NAD testing practical or scalable. We discuss the real-world impact of measuring NAD levels, from chronic illness to long COVID, and how this simple test could become as common as checking haemoglobin in the future.Jari also opens up about NADMED's regulatory journey, the ethical dilemmas of DIY supplementation, the rise of longevity tech, and how AI will transform personalised diagnostics through pattern recognition in metabolic biomarkersTimestamps:[00:00:45] Age vs Disease: What Really Impacts NAD Levels[00:02:28] Why NAD Is Essential for Life[00:03:52] How NAD Decline Signals Deeper Health Issues[00:05:05] From Niacin to NAD: Understanding the B3 Pathway[00:06:00] CE‑Marking and Regulatory Hurdles for Diagnostics[00:06:59] How NADMED Made Testing Faster and More Accessible[00:09:02] The Ethics of Supplementation Without Testing[00:10:16] The VC Path: Funding Deep‑Tech MedTech Innovation[00:14:02] Metabolic Fingerprints and Personalised Medicine[00:17:11] AI, Data and the Future of Longevity DiagnosticsConnect with Jari - https://www.linkedin.com/in/jari-n%C3%A4rhi-38b44/ Learn more about NADMED - https://www.nadmed.com/ Get in touch with Karandeep Badwal - https://www.linkedin.com/in/karandeepbadwal/ Follow Karandeep on YouTube - https://www.youtube.com/@KarandeepBadwal

In this episode, Nick Wilson of Philips Ambulatory Monitoring and Diagnostics and Darren Batara of a leading academic medical center share how health systems can elevate cardiac care through interoperability, operational AI, and strong clinical partnerships that keep patients and clinicians at the center of innovation.This episode is sponsored by Philips.

In this conversation, Kyriakos Eleftheriou is joined by Tom Livesey, CTO and co-founder of Thriva, who discusses the journey of his health tech company, which has transformed the way individuals monitor their health through innovative blood testing solutions. He shares insights on the challenges faced during the startup phase, the impact of COVID-19 on their operations, and the importance of consumer awareness in health diagnostics. Tom emphasizes the need for personalization in health insights and the role of technology in improving user experience. He also touches on the fundraising journey, navigating the NHS landscape, and the future of health tech.Chapters00:00 Intro02:44 Navigating the Challenges of Health Testing05:30 The Evolution of Thriva's Product Offering08:33 Fundraising Journey: From Startup to Success11:15 COVID-19: A Catalyst for Change14:11 The Future of Health Diagnostics16:53 Building a Sustainable Business Model19:29 Customer Acquisition and Marketing Strategies22:27 The Role of Technology in Health Monitoring24:56 The Impact of Consumer Awareness on Health27:32 The Next Decade: Predictions for Health Tech30:35 Addressing Consumer Anxiety in Health Testing33:15 The Importance of Personalization in Health Insights36:06 Navigating the NHS Landscape39:00 The Future of Home Testing and Diagnostics

Lumos Diagnostics Senior Vice President Paul Kase joined Steve Darling from Proactive to discuss a major milestone for the company — the signing of an agreement with WellStreet Urgent Care to accelerate testing and reimbursement pathways for its FebriDx® rapid host-response test. The initiative will be launched through WellStreet's joint venture with Piedmont Urgent Care in Atlanta, Georgia, marking a key step toward broader US adoption. Under the program, FebriDx will be deployed at a Piedmont Urgent Care site handling approximately 50 respiratory-infection patients per day, providing Lumos with high-quality operational data on workflow efficiency, patient outcomes, and payer engagement. Kase explained that WellStreet will procure FebriDx through PHASE Scientific and submit reimbursement claims for each test, while Pro-spectus will oversee billing data management and claims analysis. This collaborative approach is designed to generate real-world evidence to support the development of comprehensive reimbursement and coverage policies with major U.S. insurers. Pending the granting of a CLIA waiver for FebriDx, Lumos and WellStreet plan to expand the program nationwide, leveraging insights from the pilot to guide a potential rollout across more than 140 WellStreet urgent care locations across the United States. Kase added, “This partnership represents a major step in bringing FebriDx to scale in the U.S. healthcare system. By validating operational efficiency and demonstrating reimbursement viability, we're building the foundation for widespread clinical adoption of a test that helps physicians quickly differentiate between bacterial and viral infections.” #proactiveinvestors #lumosdiagnosticsholdings #asx #ldx #otc #ldxhf #LumosDiagnostics #FebriDx #PointOfCareTesting #HealthcareInnovation #UrgentCare #DiagnosticTesting #InfectionDetection #AntibioticStewardship #MedicalTechnology #ProactiveInvestors

In this episode of Ageless Future, Regan Archibald explores how to optimize cardiovascular health and even reverse your heart's biological age. Drawing on research around VO2 max and the Norwegian 4x4 training protocol, he explains how targeted exercise can reduce mortality risk and make your heart function decades younger. Regan shares personal insights from his father's near-fatal heart attack, underscoring the need for deeper diagnostics like carotid artery scans, calcium scoring, and full-body imaging. The discussion highlights key drivers of cardiovascular decline—such as inflammation, insulin resistance, mitochondrial stress, and hormone imbalances—and offers both foundational lifestyle strategies and advanced therapies including peptides, exosomes, and umbilical cord plasma. Ultimately, the episode emphasizes a proactive, measurable approach to lowering cardiovascular risk and extending healthspan.www.agelessfuture.com

Tyler O'Malley is the Vice President of Clinical Affairs, Bioinformatics, and Market Access at Exagen, Inc. Tyler shares his journey in the MedTech industry and discusses Exagen's innovative approaches to autoimmune testing solutions, including cutting-edge diagnostics for lupus and other diseases. With over a decade of experience, Tyler provides insights into the challenges and breakthroughs in the field, highlighting the significance of early diagnosis and personalized treatment, while also discussing the challenges and opportunities in effective leadership during different stages of company growth.   Guest links: https://exagen.com/ Charity supported: Save the Children Interested in being a guest on the show or have feedback to share? Email us at theleadingdifference@velentium.com.  PRODUCTION CREDITS Host & Editor: Lindsey Dinneen Producer: Velentium Medical   EPISODE TRANSCRIPT Episode 066 - Tyler O'Malley [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello, and welcome back to another episode of The Leading Difference podcast. I'm your host, Lindsey, and I am so excited to introduce you to my guest today, Tyler O'Malley. Tyler serves as Associate VP of Clinical Affairs and Market Access at Exagen, Inc., a leader in autoimmune testing solutions. In his role, he oversees clinical trials, bioinformatics, and medical policy development for Exagen's current diagnostic portfolio and pipeline of proprietary solutions. With more than a decade of experience, O'Malley has contributed to more than a dozen clinical trials focusing on clinical validity and utility evidence for autoimmune diagnostics. His expertise is widely recognized with numerous publications in esteemed peer reviewed journals, and notably, he's the first author of one of the largest clinical utility studies in lupus diagnostics. O'Malley graduated from Georgia Gwinnett College with a Bachelor of Science in biology, concentrating in biochemistry. His 11 year career in research and development and medical affairs encompass medical science, education, assay development, and clinical research coordination. Well, welcome to the show, Tyler. I'm so excited to have you here today. [00:02:01] Tyler O'Malley: Thanks, glad to be here. [00:02:02] Lindsey Dinneen: Yeah, absolutely. Well, I would love just starting off by telling us a little bit about yourself, your background, and what led you to MedTech. [00:02:11] Tyler O'Malley: Sure. So, I'm the Vice President of Clinical Affairs, Bioinformatics, and Market Access at Exagen. We're a specialty diagnostics company focused on autoimmune rheumatic diseases. So we develop proprietary testing technology for conditions like lupus, rheumatoid arthritis, Sjogren's disease, as well as many others. And yeah, our focus is trying to find solutions for patients who are dealing with what are many times challenging chronic diseases that can present themselves in very mysterious ways oftentimes. And so, these are challenges that patients have that have, for the most part, gone unsolved for many decades, and so there's a lot of opportunity out there. In terms of, myself, my background, I've been with Exagen for the past 11 and a half years. So I've been doing this for a while now, and I've worked in a couple of different areas within the organization, doing work within the lab assay development, as well as outside the lab doing clinical research, statistical analysis, which led to the bioinformatics role. And then as well as doing some work trying to align our clinical evidence with medical policy for our tests which is the market access role. So, a little bit of everything, but there are some through lines that I assure you do make some sense if you really think about it. [00:03:33] Lindsey Dinneen: Excellent. Excellent. Well, thank you for sharing a little bit about that. There's so much to dive into, but going back a little bit in your story, when you were thinking about careers-- you're a eager high school student ready to embrace college, and you're ready for the next step --is this something that you could have imagined yourself doing or has this always been a passion of yours? Or is this something you kind of found yourself in? [00:03:57] Tyler O'Malley: Not at all. So, no I, so I will say I've always been interested in autoimmunity. So that's always been something that has always piqued my interest, whether I was in high school or college. And so I guess in that sense, it's not a surprise. But the laboratory diagnostics component of it was not something that was on my radar when I was in high school or college. And I guess the journey to Exagen was, after graduating from high school, went and got a bachelor's degree in biology with a biochemistry focus. So, that's sort of my background there. And while I was getting the degree and focusing on biochemistry, I had the opportunity through a resource scholarship at Georgia Tech to work in a graduate lab, which was a really interesting experience where, you know, for a little over a year I had the opportunity to work alongside PhD candidates, postdocs, on a research project that was partially funded and get the experience and understand what it's like to work towards a PhD and what it would look like to kind of go down that path of graduate level research. And I think it had the opposite effect that it was intended to have in that it kind of showed me I didn't want to do that. So, I think in a lot of ways I was happy I had that experience 'cause it showed me before I went down that path that it was something I didn't wanna do. Nothing against it, I guess I wanted to do something that maybe had more of a translational impact, a little bit closer to the patient. And so, finished my degree, and at the time I was living in Georgia, so I finished my degree in Georgia, left and moved out to California, and ended up at Exagen by pure chance through a recruiter. And that was back in 2014, and basically just joined Exagen at the time when it was a smaller company, and grew with the company, and was fortunate enough to have the ability to learn a lot of different functions within the company as it grew, and there were a lot of different things that needed to be done a as the company was growing. And so it, it's been kind of a, an interesting ride since then. [00:06:08] Lindsey Dinneen: Yeah, absolutely. And of course all of those different experiences, I'm sure, have woven their way in, like you said. Sometimes you have to kind of look for that line, but there is one that's, apparent when you look back. So, can you talk a little bit more about the company, what it does, especially in regards to its testing technology, and I'd love to hear about some of the innovation that's just coming out of this incredible organization you're a part of. [00:06:35] Tyler O'Malley: Sure. So our our testing, again, primarily focuses on addressing unmet needs in patients who have autoimmune connective tissue diseases. And specifically we have some proprietary technology around biomarkers that help diagnose systemic lupus. And lupus is kind of the prototypical autoimmune disease in that it can manifest in just about any different way. It can show up in your skin, your heart, your lungs, your kidneys, just about any way you can imagine, and sometimes in multiple different ways. And so in that way, it can be challenging to diagnose 'cause it can look like so many different things. And much of the testing that is used for lupus or has been used traditionally is very antiquated. Antibody tests that were developed many decades ago that have been refined to some extent over the years, but for the most part are not overly sophisticated. So, what Exagen has done over the past 15 or so years is brought forward some technology, that was originally licensed from University of Pittsburgh, looking at measuring a form of the complement system, which is a part of our immune system. It's a very ancient form of our immune system. It's a collection of proteins that come together to help fight off pathogens and help clear debris to keep our our immune system healthy. And what we're able to do is measure essentially the buildup of a complement fragment that builds up on your red blood cells and on your B lymphocytes. And what this does is it gives us a unique ability to detect lupus that's much more sensitive than the conventional means. And what that means, when I say sensitivity, is that it's able to pick up more lupus patients than the conventional testing. So, one way of thinking about this is like, if you have a hundred patients in a room that all have lupus, right? Because they've been assessed by a doctor, they've been clinically diagnosed, and you were to test them, and say your conventional test is 50% sensitive, meaning half of the room would test positive on this test and the other half would test negative. This test that we're talking about here, it would pick up two thirds of the room, right, as opposed to conventional testing, which would pick up fewer patients. So, that's the kind of technology that we're trying to develop here, which is trying to be more inclusive, pick up more patients sooner, give better insights to physicians to combine with their clinical assessments such that patients can get earlier treatments and hopefully stave off some of the more kind of disastrous outcomes of the disease that come with not getting treated soon enough and not getting treated appropriately for their symptoms. [00:09:31] Lindsey Dinneen: Yeah, of course. That's incredibly important and I'm so glad that the company is working to create those solutions, like you said, because previous methods while maybe somewhat useful, are more antiquated at this point. And so it's really important to have these new strides in innovation. So as you're dealing with all of this, I'm sure that there are stories that have come up about real people having impacted lives because of the technology that your company is bringing. Do you have any examples that you could share with us about that? [00:10:05] Tyler O'Malley: Sure. Yeah, there's been a number of individuals that we've had the fortune of meeting over the years. And they come and share the story with our team. We like to bring folks in with, for example, when we bring on new sales team members, we try to bring on a patient just to be able to share their story. So, recently we had an individual, who is connected to someone who works in our organization-- again, just pure chance-- who happened to have a very unique story. So first of all, lupus, for those who don't know, is a condition that primarily affects women. Lupus is a disease that affects women at a ratio of nine to one, nine to one female to male or so, in other words, around 90% of lupus patients are women. But that's not to say that it isn't an issue for that subset of of men that do develop lupus. And in fact, the disease tends to be more severe in that 10% of lupus patients that are men. So this individual who we've had the chance to meet and hear his story, really interesting because he's-- you would never know if you met this guy-- because he's a CrossFit guy. He is probably the healthiest guy you can imagine looking at him. But he went a harrowing journey to get to his diagnosis. And it all started with, relatively -- well, I don't wanna downplay it-- but let's call it "less severe symptoms" like alopecia and rashes, things like this that sort of make you think, "Well, gee, that's strange," or "I wonder what that is all about." And then leading up to much, much more severe symptoms like severe edema and pericarditis that was ultimately life threatening. And ultimately, he was able to get the right testing and get to the right doctors, but it was not a short journey from the time that these symptoms initially presented themselves to the time where he was able to get to the test and to get to the right diagnosis and onto the right treatment. The good news is, he's in a much better place now after finding out what's causing his symptoms and getting to a treatment management plan that works for him and he's even back to getting to an exercise routine that works for him. It's maybe not exactly the same as what it was before, but I mean, that's the thing. Now, you can lead a relatively normal life with lupus. It wasn't that long ago, call it several decades ago, where the mortality rate for lupus was as high as 50% in the first year after diagnosis. Treatment advances have greatly improved that and have changed the lives of people who live with Lupus now, but it used to be a very severe diagnosis. It still is, but it's very manageable now. [00:12:54] Lindsey Dinneen: Wow. Yeah. And so catching it and having that answer to, like you said, really difficult health journey where you're just not sure what's going on. And I really appreciate you talking a little bit about how Lupus looks different and manifests itself differently in different circumstances so it can be difficult to initially diagnose. So I love the fact that the company is focusing on things like that, when caught early can maybe make a huge difference in somebody's life like the gentleman you mentioned. Thank you for sharing about that. So now your own career has been really interesting in that you have gotten to do a lot of different things within the company and learn so much. Now as you've continued to grow with the company, you've, I'm sure, developed a lot of different leadership skills along the way, and I'm curious what it's been like in that sense of your journey to embrace leadership and how do you go about it? What have you found works really well, and maybe what advice would you have for somebody who's a little bit earlier in their career? [00:13:58] Tyler O'Malley: Yeah. Really interesting question. And I, I guess, my experience was, I came into an organization that was, I think at the time, maybe in the entire company was maybe 60, 70 people. So, as you can imagine, it was a very flat organization. I reported directly to the Chief Scientific Officer when I first joined the organization as a relatively low level R&D employee. So that afforded me, I think, a unique opportunity because I was often involved with project planning and discussions that I don't know that you get that opportunity in different types of corporate settings. And I think what has proven very useful in terms of my development, and as I look back and reflect on kind of what's led me here is, I can just recall, so, so many times, especially early on in, in a startup-- which can sometimes be chaotic and there's a lot of moving parts and things are moving fast-- there would be times where I would be in meetings where I wasn't necessarily expected to do very much, I think, or contribute much. And I would just sort of observe, right? And I think there's so much you can learn through not just listening to the conversation, but the body language of the people around the table. The way that people present, the way that people take criticism, the way that they respond. It was almost like a, it was a lesson every day just watching that. And I think where I thrived and maybe added value at times was realizing when people were talking past one another and just, at times, trying to find a way to come into that and say, "Well, right, but did you consider maybe what this person was trying to communicate here?" And, you can't always resolve those sorts of situations, but sometimes you can. And that's really valuable when you can help two individuals get past an impasse like that. So, and I think it helps you build credibility doing that too, being a bridge builder in that sense. And, and I think, that was something I don't know-- whether intuitively or purely by accident, I don't know-- I figured out over time was that, maybe as a young person in your career, sometimes it can be easy to get caught up on sort of the X's and O's of your job, whatever it is that you're doing-- if you're a computer programmer, you're doing bioinformatics or whatever the case may be-- you can get really caught up in the technical skills that you're trying to hone and develop. But there's so many soft skills that you have to build as well at the same time. And there's the relationships that you build, as well, that you don't know when you're gonna need them or when they'll pay off. But things change at organizations and you're glad when you have those relationships when it comes time to need them. [00:16:51] Lindsey Dinneen: Yeah. Absolutely. Yeah. I love your discussion on the idea of being a bridge builder, because I've been thinking a lot about that recently where there's so much unintentional missed communication, just literally just passing by where, one person is saying something, the other person's saying something, and as an outsider, you're able to have a little bit of a distance to go, "Oh, you're kind of saying the same thing, but I'm not sure that you guys realize that, and here's how." Yeah, that translating is a really important skillset and a fun one when you can nail it down. So as you look towards the future of your own career and the company's trajectory, what are some things that you're looking forward to? [00:17:35] Tyler O'Malley: Well, we obviously have a number of exciting pipeline initiatives that bring a lot of energy to me as I think about what we're trying to do going forward. I'm excited about where the company is headed in terms of its trajectory. I've described my time at the company as, even though I've been at the same company for 11 and a half years or so, I really feel like I've worked for three different companies in that time, in that, there was a period of time that was a startup up until the point the company went public. And then there was this time from when the company was public, where we raised a lot of money, there were a lot of expectations and didn't exactly kind of work out exactly as we had hoped. And then there was a leadership change. And now we're sort of in this third phase now where the arrow's pointing up and we have realigned our strategy here and we found a way to be sustainable and to be able to continue to build on something where hopefully we can continue to find interesting technology that's out there. We have an ongoing partnership with, as an example, Johns Hopkins University to try to develop a test to help address lupus nephritis. So this is a particular form of organ manifestation of lupus. It's one of the more common manifestations of lupus, and one of the more devastating forms of lupus, in that almost 50% of lupus patients will have kidney involvement at some point in their disease. And as much as 10 to 20% of patients who do have lupus nephritis will go on to unfortunately develop end stage kidney disease and require dialysis or kidney transplant. So it's obviously life altering and can be, very impactful to individuals. So, to be able to work on something like that and be able to potentially alter the trajectory of someone's life in that way is pretty cool to think about. And, not everyone gets to do that. I mean, it's not that other jobs aren't meaningful, it's just not everyone gets the opportunity to do that kind of thing. And if you can also find joy in what you're doing in your job. I think that's also great too. I mean, it's really cliche, the things people say, and so I won't do it. The whole, like, " If you like what you do, you never work." Believe me, it's work. I do feel like I'm working sometimes, for sure, but I can't complain. I do, for the most part, have fun with what I'm doing. I'm fortunate enough, I have a great team of people, well-- three teams of people-- that I really enjoy working with, and being able to work with people and see them grow and develop and be a part of that is also super rewarding as well too. So, yeah, I'm just, I'm having a lot of fun. [00:20:26] Lindsey Dinneen: Yeah. Excellent. Wonderful. Well, gosh, I'm gonna pivot the conversation just for fun a little bit. Imagine that you were to be offered a million dollars to teach a masterclass on anything you want. Now, this could be within your industry, but it doesn't have to be. What would you choose to teach? [00:20:45] Tyler O'Malley: I think that-- maybe this is kind of fun, probably not-- but I think that ,I don't know why, and it's funny because it's-- I don't even know if this qualifies because I don't even know how I would teach it-- but I think I'm fairly good at guesstimating numbers and it's really useful in that it helps in a lot of different situations to be able to shortcut math. And to be clear, it's not that I'm doing long division in my head or anything like that, but it's, if you can kind of shortcut and get the approximate number, it can be really useful. And it's a nice kind of party trick too kind of thing. Again, I don't know how I would teach it 'cause it's sort of like it's up here, and I don't know how I would externalize that, but yeah, that's something I feel like would be kind of cool to figure out how I could teach that. [00:21:35] Lindsey Dinneen: Absolutely. Yeah. It's a superpower. So it would be very cool to try to then-- you've got this innate ability-- so then to try to break it down into how does somebody else develop the skill sets that you just sort of possess, and go from there. That would be really entertaining. I love it. Great answer. Okay. And then the next question is, how do you wish to be remembered after you leave this world? [00:21:59] Tyler O'Malley: Yeah. Well, that's a deep question. I think that the most meaningful impact that you can have is the impression you leave on the people that you interacted with, right? And I think, for me, I would just hope that the people that I've had the chance to spend time with-- obviously family, friends, people I worked with, people who worked on my teams-- I would just hope that as they would reflect on the time that we had together, that it would be a memory that was time well spent and that hopefully there are some good shared experiences that we had and that hopefully I left something that was meaningful. But as it relates to the work that we're doing, I hope that the impact that we're having-- some of it has a longer reach than even what we can see today, 'cause I think, truly being selfless is trying to build things that you'll never realize the benefit of: planting trees that you'll never sit under yourself. It's for someone else down the line in the future. [00:23:14] Lindsey Dinneen: Yeah. Yeah. I love thinking about it in those terms too: being willing to do your bits of good and let them go out into the world and not necessarily know the ripple effects and still use that as a worthwhile use of your time. I love that. And then final question, what is one thing that makes you smile every time you see or think about it? [00:23:39] Tyler O'Malley: Yeah, I think the easy answer is probably my kids. So I have two kids, and that's kind of the reprieve from the work life and kind of focusing on all this important stuff that we're trying to do here at work, but being able to kind of break away from that and focus on building them up and watching them grow and develop and become their own person is really cool. It's obviously a unique experience and it's a nice thing to be able to think about when you need something to kind of bring you back up. [00:24:12] Lindsey Dinneen: Yeah, absolutely. Just a different way of looking at the world from such a fun perspective. I love that. [00:24:19] Tyler O'Malley: Yeah. [00:24:20] Lindsey Dinneen: Yeah. Well, Tyler, this has been such a great conversation. I so appreciate your time today telling us a little bit about your story, the company, and all the incredible work that you guys are doing to change lives for a better world. And we are so honored to be making a donation on your behalf as a thank you for your time today to Save the Children, which works to end the cycle of poverty by ensuring communities have the resources to provide children with a healthy, educational, and safe environment. So thank you so much for choosing that charity to support, and thank you so much for being here and thank you for doing what you do. [00:24:59] Tyler O'Malley: Thank you. It's it's been a pleasure. [00:25:01] Lindsey Dinneen: Excellent, and thank you also to our listeners for tuning in, and if you're feeling as inspired as I am, I'd love it if you'd share this episode with a colleague or two and we'll catch you next time. [00:25:14] Dan Purvis:  The Leading Difference is brought to you by Velentium Medical. Velentium Medical is a full service CDMO, serving medtech clients worldwide to securely design, manufacture, and test class two and class three medical devices. Velentium Medical's four units include research and development-- pairing electronic and mechanical design, embedded firmware, mobile app development, and cloud systems with the human factor studies and systems engineering necessary to streamline medical device regulatory approval; contract manufacturing-- building medical products at the prototype, clinical, and commercial levels in the US, as well as in low cost regions in 1345 certified and FDA registered Class VII clean rooms; cybersecurity-- generating the 12 cybersecurity design artifacts required for FDA submission; and automated test systems, assuring that every device produced is exactly the same as the device that was approved. Visit VelentiumMedical.com to explore how we can work together to change lives for a better world. 

Lyme disease shouldn't be a guessing game.In this episode, Nicole Bell—MIT/Duke engineer, author of What Lurks in the Woods, and CEO of Galaxy Diagnostics—shares how her husband's undiagnosed Lyme and co-infections (Bartonella, Babesia) led to a tragic outcome… and why that drove her mission to change the standard of care for tick-borne illness.We break down:-Why antibody tests miss stealth infections -How direct detection (PCR, digital PCR) + sample enrichment improve sensitivity-Smart strategies to test co-infections (e.g., urine antigen for Borrelia, blood enrichment for Bartonella)-Practical tips (timing, pre-test movement/sauna, re-testing windows)-Advocacy: finding clinicians, navigating “normal” labs, and pushing for answersResources mentioned:Galaxy Diagnostics: galexydx.com (education center + testing info)Center for Lyme Action “State of Lyme Disease Research”Pathways for non-licensed practitioners (via Mosaic Diagnostics, Evexia, Rupa) – coming online soonIf you or a loved one is stuck with “inconclusive” results, this conversation offers a roadmap—grounded in science and born from lived experience.

Send us a textIn this episode Live from the 2025 DSG Conference, Paul, Steve, Bryn and Ryan (Buda) Suda talk Y-Series refrigerant flow and offer helpful tips on diagnostics.Thanks for listening! Please visit www.mitsubishicomfort.comContact us at metustechshow@hvac.mea.com

Cats deserve cancer breakthroughs too! Dr. Sue Ettinger, DVM, DACVIM (Oncology), shares what's on the horizon for feline cancer testing in the next episode of the Purr Podcast. Known on social media as Dr. Sue Cancer Vet, she is an international speaker, author, & vlogger. She is a board-certified specialist in medical oncology. She received her veterinary training at Cornell University College of Veterinary Medicine. She completed her residency in medical oncology at the Animal Medical Center in NYC in 2003.Thanks for tuning in to the Purr Podcast with Dr. Susan and Dr. Jolle!If you enjoyed today's episode, don't forget to subscribe, rate, and leave us a review—it really helps other cat lovers and vet nerds find the show. Follow us on social media for behind-the-scenes stories, cat trivia, and the occasional bad pun. And remember: every day is better with cats, curiosity, and maybe just a little purring in the background. Until next time—stay curious, stay kind, and give your cats an extra chin scratch from us. The Purr Podcast – where feline medicine meets feline fun.

If you're enjoying the content, please like, subscribe, and comment! Dr. Schwartz's Links: Website: https://www.theodorehschwartzmd.com/ Book: https://www.penguinrandomhouse.com/books/734286/gray-matters-by-theodore-h-schwartz/ Theodore H. Schwartz, MD graduated Magna Cum Laude in Philosophy and English from Harvard University and Magna Cum Laude in Neuroscience from Harvard Medical School. After completing his residency and chief residency in Neurosurgery at The Neurological Institute of New York at Columbia-Presbyterian Medical Center, Dr. Schwartz spent a year at Yale-New Haven Medical Center where he received advanced fellowship training in epilepsy and brain tumor surgery. He completed a post-doctoral fellowship at the Max Planck Institute in Munich, Germany funded by the Van Wagenen Fellowship and the Von Humboldt Society. Dr. Schwartz spent 25 years as a Professor of Neurosurgery, Otolaryngology, and Neuroscience at Weill Cornell Medical College, New York Presbyterian Hospital. He was named David and Ursel Barnes Professor in Minimally Invasive Surgery, the first endowed professorship in the department, Vice-Chairman of Clinical Research, the Director of Anterior Skull Base and Pituitary Surgery, Co-Director of Surgical Neuro-Oncology, the Director of Epilepsy Surgery, and ran a basic science laboratory investigating the causes and treatment for epilepsy. He has received K08, R01 and R21 funding from the NINDS for his research and has served on several NIH review committees.Dr. Schwartz's book Gray Matters: A Biography of Brain Surgery, published by Dutton/Penguin-Random House, was selected by The Economist as one of the best books of 2024. His nonfiction writing has been featured in the Wall Steet Journal, the Boston Globe, Psyche Magazine, and The Psychologist. Dr. Schwartz is currently the Founder and CEO of a med tech device company called illumination Diagnostics._______________________Follow us!@worldxppodcast Instagram - https://bit.ly/3eoBwyr@worldxppodcast Twitter - https://bit.ly/2Oa7BzmSpotify - http://spoti.fi/3sZAUTGYouTube - http://bit.ly/3rxDvUL#neuroscience #surgeon #medschool #medical #neurosurgeon #surgery #medicine #medicalstudent #cte #tbi #trauma #traumaticbraininjury #concussion #subscribe #explore #explorepage #podcastshow #longformpodcast #podcasts #podcaster #podcasting #worldxppodcast #viralvideo #youtubeshorts

How are leading urologic oncologists using advanced biomarkers and artificial intelligence to refine the diagnosis and management of non-muscle invasive bladder cancer (NMIBC)? In the opening episode of our 2025 NMIBC Creator Weekend™ series, host Dr. Bogdana Schmidt engages in an insightful, in-studio discussion with Dr. Anne Schuckman and Dr. Piyush Agarwal about contemporary strategies and challenges in the diagnosis of non-muscle invasive bladder cancer.---This podcast is supported by an educational grant from Ferring Pharmaceuticals.---SYNPOSISThe doctors emphasize the importance of having an experienced cytopathologist and discuss the use of different biomarkers and imaging modalities in bladder cancer diagnosis. The conversation delves into risk stratification, patient management strategies, and the evolving role of technology and artificial intelligence in enhancing diagnostic accuracy. The experts also share their perspectives on future advancements and their potential impact on clinical practice.---TIMESTAMPS00:00 - Introduction04:05 - Surveillance and Follow-Up Strategies10:10 - Biomarkers in Bladder Cancer18:02 - Blue Light Cystoscopy and Patient Comfort30:56 - Risk Assessment and Counseling42:56 - Future of Bladder Cancer Diagnostics47:00 - Concluding Thoughts---RESOURCESCxBladder Studyhttps://www.sciencedirect.com/science/article/pii/S1078143923000091Lars Dyrsakjot Study on Tumor Markershttps://pmc.ncbi.nlm.nih.gov/articles/PMC7690647/The Bridge Trialhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10515442/

Send us a textLive from Pathology Visions 2025 in San Diego, I share highlights from Day 2 of the world's leading digital pathology conference, where experts explored how AI, empathy, and training are shaping the next generation of pathologists.This episode captures the shift from technology as a tool to technology as a bridge — helping us connect with patients in more meaningful ways.What I Talk About1️⃣ From Pixels to Patients We've built the infrastructure; now it's about applying it. Pathology is no longer just digital — it's personal, accessible, and human-centered.2️⃣ Dr. Leah Lijah Joseph's Keynote — Pathologists as Patients Dr. Joseph, a cancer pathologist and survivor, shared her journey from diagnosing others to understanding her own slides. She now runs a patient pathology clinic, empowering people to see and learn from their own tissue samples.3️⃣ The Power of Visualization Dr. Joseph described how visualization and mental imagery support healing — a reminder that empathy and imagination can coexist with precision science.4️⃣ AI & Imaging Innovation From Google Research's JPEG AXL format reducing file size by 30%, to discussions on color fidelity with DICOM's David Clooney, we explored how innovation and accuracy must move hand-in-hand.5️⃣ Cytology Goes Digital With Hologic's Genius Digital Diagnostic and AIXMed's AI-assisted QC, cytology is entering a new era — faster, more accurate, and fully traceable through 100% AI quality control.6️⃣ The Human Side of AI I also share a personal story about my mother's medical experience — and how even with all the tech, empathy remains the missing link. AI can't replace compassion, but it can help us focus on it by automating what takes time away from patients.Key TakeawaysAI is enhancing accuracy and accessibility in diagnostics.Pathologists are taking on more patient-facing roles.Cytology digitization is revolutionizing quality and speed.Innovation must balance efficiency with color and data integrity.Empathy and communication will always define great medicine.I hope this episode helps you see how AI, empathy, and education are shaping the next era of diagnostics.Let's continue building the bridge from pixels to patients, one slide at a time.

Beyond the Calcium Score: Longevity & Your Own Stem CellsClick On My Website Below To Schedule A Free 15 Min Zoom Call:www.Over40FitnessHacks.comOver 40 Fitness Hacks SKOOL Group!Get Your Whoop4.0 Here!Dr. Khoshal Latifzai - Rocky Mountain Regenerative Medicinewww.RMRM.comGuest: Dr. Kal Khoshal, MD (Rocky Mountain Regenerative Medicine, Boulder, CO) Focus: Longevity, prevention-first diagnostics, and regenerative therapies (peptides, hormones, PRP, stem cells).Origin story & model: After Dartmouth Med and a Yale EM residency, Dr. Khoshal left the ER due to burnout and the “band-aid” nature of conventional care. He built a cash-pay concierge clinic to spend 60–90 minutes with patients, run deeper diagnostics, and create long-term, prevention-focused plans. He does not bill insurance (patients keep catastrophic coverage), which lets him order better tests and avoid the admin churn.Diagnostics that actually predict risk:Starts from top U.S. mortality drivers (cardiovascular disease, diabetes, cancer, trauma in older adults) and then chooses biomarkers that best reflect true risk, repeating them multiple times per year and explaining results in plain English with written notes.Cancer screening: uses blood tests that detect circulating tumor DNA (ctDNA) as an early, broad screen; positives are followed by imaging (often full-body MRI or targeted MRI/PET).Heart disease: warns that calcium-score CT can miss early non-calcified plaque (common in 40s–60s). Prefers imaging that sees soft plaque before calcification.Whole-body MRI: advocates this for catching issues (like leg artery disease) that localized scans miss—especially relevant to older adults.Therapies & philosophy:Tools include peptides, hormones, PRP, and stem cells, but only after foundations: exercise, nutrition, and social health—there's no shortcut.Stem cells: strongly prefers autologous (your own) cells that are culture-expanded in a sterile lab, stored, and used over time (IV for systemic repair; guided injections for joints/spine).Cautions against routine allogeneic (donor/cord) cells due to immune reactions and potential long-term autoimmunity.Banking earlier is better, but even older adults can benefit; he shared an 80-year-old scoliosis case that avoided major spine surgery after one procedure.In-clinic process: mini-lipo harvest → lab isolation & expansion → cryostorage (annual maintenance fee ~$350).Advises skepticism about overseas clinics and some cord-blood banks with variable quality/control.If you're interested in online personal training or being a guest on my podcast, "Over 40 Fitness Hacks," you can reach me at brad@over40fitnesshacks.com or visit my website at:www.Over40FitnessHacks.comAdditionally, check out my Yelp reviews for my local business, Evolve Gym in Huntington Beach, at https://bit.ly/3GCKRzV

⁠⁠Amardeep Parmar⁠⁠⁠ from Bae HQ welcomes ⁠⁠⁠⁠⁠Srijan Jindal⁠, Founder at ⁠⁠⁠⁠Innotive Diagnostics⁠⁠⁠⁠.

In this episode of The Healthy Mouth Movement, I sit down with Reed Davis, a double board-certified holistic health practitioner, certified nutritional therapist, and the visionary founder of Functional Diagnostic Nutrition (FDN). With more than 25 years in the field and over 5,000 practitioners trained worldwide, Reed shares how he pioneered an approach that helps people take charge of their own health through testing, education, and self-directed healing. We dive into Reed's journey from environmental law to holistic health, how “metabolic chaos” disrupts the body's systems, and the hidden connections between the mouth, hormones, digestion, and overall wellness. You'll hear why testing instead of guessing is key, the importance of taking responsibility for your own health, and why true healing starts with understanding the body as a whole. Connect with the guest:Website - https://www.functionaldiagnosticnutrition.com/Facebook - https://www.facebook.com/FunctionalDiagnosticNutrition/Instagram - https://www.instagram.com/fdntraining/You Tube - https://www.youtube.com/channel/UC7xDnEKCe9gKeWZ2vbE3C8wLinkedin - https://www.linkedin.com/company/san-diego-natural-health-&-fitness-ctr/Twitter - https://twitter.com/FDNtraining This conversation reminded me that wellness truly begins from the top down—what we believe, how we breathe, and what we put into our mouths all impact the rest of our body. Don't guess when it comes to your health—test. When you understand what your body needs, you can make lasting changes that transform how you feel and function. If you enjoyed this episode, please rate, review, and share The Healthy Mouth Movement Podcast. Your feedback helps others discover this show and take the first step toward healthier living—because wellness begins with a smile. Check out The Mind Mouth Body SHIFT Method -- https://shereewertz.com/academy Book a consultation today:I am always here to help answer any question and schedule a 15 minute call with me. If I can not help, I can get you to a provider that can.https://shereewertz.com/15-min

Welcome to The Trade Talks Live, where we celebrate the blue-collar trades and everything they stand for! Join us every weekday from 10-11 AM as we dive into national news, review trade websites, and share tips on mindset growth to help you succeed. Don't miss this hour of insights, inspiration, and practical advice! A big thank you to Leak-Pro for sponsoring this episode of The Trade Talks Live! Register for my FREE webinar! www.justmetroger.com LeakPro provides state-of-the-art leak detection solutions specifically designed for plumbers, helping professionals pinpoint hidden leaks with accuracy and efficiency. By utilizing advanced acoustic technology and digital sensors, LeakPro allows plumbers to reduce unnecessary damage, saving time and money on every job. LeakPro's tools are essential for detecting slab leaks, pipe leaks, and irrigation system failures without invasive measures. Whether working in residential or commercial plumbing, LeakPro offers cutting-edge solutions that enhance service quality. For more information, visit www.leak-pro.com or call 1-888-853-2577. Tradesmen built America. This is the "Blue Collar Channel"... Where you can listen to the top tradespeople around the world. Everything you need to learn about getting into the trades, becoming the best tradesman, starting your own business, and using networking and social media... To GROW in the trades!!!

In this episode of the Used Car Dealer Podcast, Zach talks with Cole Reiken, Managing Director of Blue Driver, to unpack how smarter diagnostics and data-driven tools are reshaping dealership profitability and customer trust.Cole shares lessons from his career at Impel.AI, Open Lane, and Canadian Black Book, and how those experiences inform his leadership at Blue Driver. He dives into the balance of serving both DIY consumers and enterprise dealers, the challenge of system fatigue in dealerships, and why seamless workflow integration is key to adoption.The conversation covers EV diagnostics, predictive insights, fraud protection, and how Blue Driver Max helps dealers avoid costly trade-in surprises. Cole also looks ahead at the role of data integration, battery health, and a future where diagnostics follow the vehicle through its entire lifecycle.Whether you're focused on reducing reconditioning risk, improving appraisal accuracy, or preparing for EV adoption, Cole's insights offer practical takeaways for independent and franchise dealers alike.⏱️ Key Questions & Timestamps 00:00 – Intro & Cole's background at Impel.AI, Open Lane, Canadian Black Book 04:20 – How do you balance consumer vs. enterprise diagnostic needs? 07:18 – What does Blue Driver offer today for consumers and dealerships? 11:31 – What are the headwinds to adoption at the dealership level? 13:40 – How are you preparing for EVs and software-defined vehicles? 15:56 – What diagnostic innovations will most impact dealers in the next 5 years? 19:28 – What's your vision for consumer vs. dealer diagnostics by 2030? 23:20 – Q1: What product or feature has surprised you most in development over the past year?24:12 – Q2: What's one app you use every single day?24:29 – Q3: What's one thing in the auto industry that you think is overhyped right now?25:35 – What updates and events are coming up for Blue Driver?

What role does communication play in building health systems and addressing global health challenges? Jed Beitler discusses his work with non-governmental and international organisations, exploring lessons from Sub-Saharan Africa, strategies for fighting major diseases, and the importance of collaboration in global health. Timestamps: 00:56 – Early career 02:37 – Sub-Saharan Africa 06:08 – Tackling HIV 07:53 – Not-for-profit organisations 11:43 – Diagnostics

Full name: Thierry L. BernardTitle: Chief Executive OfficerWebsite: https://www.qiagen.com/usTicker: $QGENBiography: Thierry Bernard joined QIAGEN in February 2015 to lead the company's growing presence in molecular diagnostics, the application of Sample to Insight solutions for molecular testing in human healthcare.He was named Chief Executive Officer in March 2020 after serving in this role on an interim basis and became a member of the Managing Board in 2021.Previously, Mr. Bernard held roles of increasing responsibility during 15 years with bioMérieux SA, most recently as Corporate Vice President, Global Commercial Operations, Investor Relations and the Greater China Region, and held senior management roles in several other leading international companies.He was named Chair of the AdvaMedDx Board of Directors in March 2023, a U.S. industry trade association, and joined the Board of Directors of Neogen Corporation (NASDAQ: NEOG) in 2024.Mr. Bernard has earned degrees and certifications from Sciences Po, the London School of Economics, the College of Europe, Harvard Business School, Centro de Comercio Exterior de Barcelona. He has been appointed Conseiller du Commerce Extérieur by the French government.

Deze zomer werd laboratorium Clinical Diagnostics getroffen door een enorme ransomware-aanval. Zeer gevoelige gegevens van meer dan 850.000 Nederlanders werden op het dark web gepubliceerd. Wat zegt dit over de databeveiliging binnen ons zorgsysteem? En brengt dit ons vertrouwen in de zorg - en daarmee ook onze gezondheid - in gevaar?Techjournalist Daniël Verlaan zag een deel van de gelekte gegevens in en vertelt wat hij daar precies aantrof. Samen met techjurist Lisette Meij bespreken Harm en Dave welke juridische gevolgen Clinical Diagnostics en Bevolkingsonderzoek Nederland boven het hoofd hangen, en kijken ze naar de mogelijkheden voor slachtoffers: waar moet je waakzaam voor zijn als jouw gegevens zijn betrokken bij een lek?Ellen Mok belt namens de Digitale Dolle Mina's in over de politieke nasleep van de hack en legt uit hoe zij strijdt voor de belangen van de - veelal vrouwelijke - slachtoffers.Tips:Podcast ‘The Kill List'FraudehelpdeskZet de verbetering van generatieve AI uit op LinkedInPodcast ‘NOOD'Het Digitale Front wordt mede mogelijk gemaakt door KPMG.Zie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

In this episode of The Behavioral Observations Podcast, I talk with Grant Sickle, former Amazon product leader and current head of product at Frontera, a company building AI-powered platforms to improve autism care. Grant shares how his team is developing assessment and diagnostic tools to shorten waitlists, streamline reporting, and support clinicians in delivering more efficient ABA therapy. We also discuss how Frontera's digital phenotyping app enables HIPAA-compliant behavior tracking, parent engagement, and asynchronous supervision — while addressing the issue of fraud prevention. This conversation highlights both the promise and the challenges of using AI in clinical settings, emphasizing the importance of clinician oversight, robust validation, and feedback loops. Grant also shares insights from Frontera's home-based pilot program, which helps parents capture real-world behavior data to support better generalization and treatment planning. Whether you're a BCBA, RBT, parent, or researcher, this episode offers a fascinating look at the intersection of technology, autism care, and ethical ABA practice. What You'll Learn in This Episode How Frontera is building AI-driven assessment and diagnostic tools for autism care Why clinician oversight remains critical in AI-powered healthcare solutions Insights into fraud prevention in ABA therapy using videographic evidence and facial recognition How home-based video tracking is supporting behavior generalization and parent engagement The challenges of adoption among BCBAs versus RBTs and parents Future directions for AI in ABA, including outcome measurement and identifying autism subpopulations The technique Amazon's founder used to find and correct problems Links to Related Resources The inaugural Frontera Series interview with Founder, Amol Deshpande AI, and the Future of Clinical Tools with Sydney Holmes Follow Frontera on LinkedIn and Instagram An overview of fraudulent billing practices in ABA Why Jeff Bezos' email address is publicly available

Like the show? Show your support by using our sponsors.Promotive can help you find your dream job. Touch HERE to see open jobs.Need to update your shop systems and software? Try Tekmetric HEREIn this episode, Jeff is joined by Mathieu Patenaude, a mobile heavy truck technician from the Ottawa area. Mathieu shares his journey from working for a school bus company to running his own mobile diagnostic business, explaining the challenges of adapting to rapidly changing truck technology and industry standards. They both talk about the challenges of working in harsh Ottawa winters, the unique demands of fleet maintenance, and the importance of thorough diagnostics and road-testing in the trucking world.Timestamps: 00:00 Ottawa Business Overview with Matthew06:08 Old School Car Troubleshooting13:03 Ottawa's Troubled Transit Project16:57 Parking Lot Truck Challenges21:34 Trailer Safety Overload Experience26:20 Renting Trucks vs. Specialized Equipment35:11 Pursuing a Career with Mercedes?37:16 "Tech Diagnostics: Knowledge Builds Over Time"43:47 Rising Door Rates in Canada47:29 "Shop Pranks with FUE Cans"56:12 "Rethinking Trade Apprenticeships"58:15 "Encouraging Thoughtful Problem Solving"01:08:05 Importance of Failure Analysis01:08:43 Incomplete Failure Analysis Practices01:15:40 Procrastinating Vehicle Maintenance Woes01:20:54 Changing Car Culture Impacting Youth01:25:32 Paving His Own Path01:30:48 Tech Distractions in the Workplace01:39:01 Transmission Fluid Level Check Process01:45:46 Handle Both Car Batteries01:47:07 Critiquing from an Ivory Tower01:51:39 Hidden Car Defects Dilemma Follow/Subscribe to the show on social media! TikTok - https://www.tiktok.com/@jeffcompton7YouTube - https://www.youtube.com/@TheJadedMechanicFacebook - https://www.facebook.com/profile.php?id=100091347564232

ATTENDEESDeclaime, Spectacular Diagnostics, Keith Rollins, Daniel OlneyAGENDANew BusinessDiscuss what lead to the creation of WHAT IF and where it sits in the catalog of everyone involved.  Discuss WHAT IF in detail. intro and outro by andrew

In this episode of the Ageless Future podcast, Regan Archibald sits down with Dr. Natalia Mitin, a leading researcher in immunology and longevity, to discuss how aging is fundamentally driven by the immune system. Dr. Mitin breaks down complex mechanisms like immunosenescence and T-cell exhaustion and introduces her company's breakthrough SapereX test, which measures immune system age with high precision. They explore why traditional longevity biomarkers like telomeres often miss the mark, and how direct T-cell gene expression provides clinicians with actionable insights. This episode also covers key interventions—from stem cell support to senolytics—and emphasizes the importance of tailoring protocols based on actual biological needs rather than trends. Dr. Mitin and Regan underscore a powerful message: true longevity starts with personalized diagnostics and measured interventions, not guesswork. www.saperex.comhttps://www.linkedin.com/in/nataliamitin/ 

What if your biggest marketing obstacle isn't bad data, but the wrong diagnosis? In this episode of StrategyCast, learn how rigorous diagnostics fuel smarter strategies, why true differentiation matters, and how brand and performance marketing can win, together!And don't forget! You can crush your marketing strategy with just a few minutes a week by signing up for the StrategyCast Newsletter. You'll receive weekly bursts of marketing tips, clips, resources, and a whole lot more. Visit https://strategycast.com/ for more details.==Let's Break It Down==06:20 Opportunity Assessment Limitations10:20 "Marketing Insights at Pepper & Hershey"12:07 Bringing Consumer Insight to Operations17:25 "Strategic Differentiation for Brand Growth"19:55 "Diagnostics to Strategy: Making Choices"24:41 Assessing Strategic Opportunities26:59 Brand Stretching Limits: Arm & Hammer31:55 Integrated Marketing Key to Success34:49 Ad Tech Mistakes and ROI Challenges37:24 Marketing Basics: Broad, Inclusive Reach==Where You Can Find Us==Website: https://strategycast.com/Instagram: https://www.instagram.com/strategy_cast/Facebook: https://www.facebook.com/strategycast==Leave a Review==Hey there, StrategyCast fans!If you've found our tips and tricks on marketing strategies helpful in growing your business, we'd be thrilled if you could take a moment to leave us a review on Apple Podcasts. Your feedback not only supports us but also helps others discover how they can elevate their business game!

We break down the core Circumplex orientation - Satisfaction (growth) vs Security (protection). Learn how state of mind drives behavior, why confidence is quiet, and practical ways to shift from defensiveness to growth. View the full show notes here: https://www.human-synergistics.com.au/resources/culture-insights-blog/satisfaction-vs-security-what-it-is-and-why-it-matters-culture-bites-248/ Consulting Solutions: https://www.human-synergistics.com.au/our-services/consulting/ Diagnostics: https://www.human-synergistics.com.au/our-diagnostics/ Accreditation: https://www.human-synergistics.com.au/become-accredited/

Send us a textThis discussion on ways to improve MASH patient management comes from the early July roundtable on "Major Issues of the First Six Months of 2025." As a reminder, that roundtable included the three co-hosts (Louise, Jörn Schattenberg and Roger Green) Roger drives this conversation, focusing on two very different, yet very important issues: the first is the increasing dynamism of the in-office scanning market, with leader Echosens developing new products and services, while companies like e-Scopics, Sonic Incytes, and Mindray (Hepatus) are introducing new devices with competing profiles. Roger discusses the idea that some scanners keep all data resident in the machine, while others send it immediately to the cloud. Louise suggests that while we should welcome any reliable scanning device to the market, Echosens has a significant advantage in terms of data richness and depth when compared to all competitors. (NOTE: This benefit became clearer when Echosens submitted a Letter of Intent to the FDA to qualify liver stiffness measurement (LSM) using VCTE, as found in FibroScan, as a reasonably likely surrogate endpoint in clinical trials for MASH.Separately, he lists some concerns about how the Trump Administration's focus on cutting services to the poor, coupled with Robert F. Kennedy Jr.'s distrust of pharmaceuticals and mainstream health research, might limit the number of Americans with access to healthcare and the kinds of care they can access. At the end of this conversation, Roger asks Jörn and Louise what they consider major issues for the next six months.

Sales legend and trainer Steve Gielda—co-founder of Ignite Selling—joins Samuel to break down what truly drives performance in medical device, pharma, biotech, and diagnostics. Steve traces his path from selling 3M copiers out of a van to leading life-sciences consulting with Neil Rackham (of SPIN Selling) and building Ignite's simulation-based, gamified training that accelerates pipelines and product launches. We get tactical fast: how today's top reps think strategically, map real stakeholders (beyond the “friendly” contacts), and use smarter questions that challenge clinical and business assumptions—not just needs. Steve explains when SPIN still shines, where Challenger-style questions raise the bar, and why role-playing strategy is as critical as role-playing the call. For frontline managers, Steve lays out the playbook: coach early in the pipeline, ask more than you tell, know when to sell vs. when to coach, and—yes—let your reps fail on safe calls so they learn to win without you. We dive into work ethic vs. knowledge, turning average reps into top performers, and the signals that a high producer is (or isn't) ready for leadership. If you want practical frameworks to sharpen your questioning, focus your account strategy, and elevate your team's coaching culture, this episode delivers candid insights you can apply on your very next call. Connect with Steve: LinkedIn Connect with Me: LinkedIn Love the show? Subscribe, rate, review, and share! Here's How » Want to connect with past guests and access exclusive Q&As? Join our EYS Skool Community today!

Peter Maurer, Assistant Professor of Molecular Engineering at the University of Chicago Pritzker School of Molecular Engineering, speaks with Pitt's HexAI podcast host, JordanGass-Pooré, about the future impact of quantum sensing on biomedical research and diagnostics.Peter's research lab leverages the extreme environmental sensitivity of quantum systems to develop powerful sensors suitable for cutting-edge biological research that are optically addressable and can operate under ambient conditions. He outlines both near-term and future applications of powerful quantum sensors in pathology and laboratory medicine. He provides a key example of how these sensors could enable a new type of nanoscale NMR spectroscopy, capable of measuring magnetic fields from biomolecules to non-invasively probe their chemical information and signaling pathways. In the near future, he points to diagnostic tools, currently being developed by companies, that use the unique optical signatures of quantum sensors for highly sensitive, background-free protein detection in small volumes. For the long term, he envisions the technology as a "field opener" for studying protein aggregation in neurodegenerative diseases like Alzheimer's and Parkinson's.Peter outlines how AI can be applied to analyze complex data from sensors that respond to multiple environmental factors and highlights the challenge of bringing together experts from quantum technology, biophysics, and medicine who can "talk each other's language.” He also touches on how the use of synthetic data in quantum sensing is a "completely under-appreciated" area with the potential to analyze complex environmental properties that would otherwise be missed by looking at single types of measurements. To advance the field from academic proofs-of-concept to clinical tools, he stresses the need for collaboration with academic and industry partners who can help engineer robust, "turnkey" systems that can be widely tested and used.The University of Pittsburgh Health and Explainable AI podcast is a collaborative initiative between the Health and Explainable AI (HexAI) Research Laboratory in the Department of Health Information Management at the School of Health and Rehabilitation Sciences, and the Computational Pathology and AI Center of Excellence (CPACE), at the University of Pittsburgh School of Medicine.Hosted by Jordan Gass-Pooré, a health and science reporter, this podcast series explores the transformative integration of responsible and explainable artificial intelligence into health informatics, clinical decision-making, and computational medicine. From reshaping diagnostic accuracy to enhancing patient care pathways, we'll highlight how AI is creating new bridges between researchers, clinicians, and healthcare innovators. Led by Ahmad P. Tafti, Hooman Rashidi and Liron Pantanowitz, the HexAI podcast is committed to democratizing knowledge around ethical, explainable, and clinically relevant AI. Through insightful conversations with domain experts, AI practitioners and students will spotlight the latest breakthroughs, discuss real-world applications, and unpack the challenges and opportunities that lie ahead in responsible AI in healthcare. So whether you're a student, practitioner, researcher, or policymaker, this is your gateway to the future of AI-powered healthcare

Lauren Rosenberg, a highly experienced Physician Associate, has dedicated nearly two decades to Internal Medicine and Health Optimization. Driven by a passion for preventative care, Lauren founded Vent Health to shift the focus from disease treatment to prevention. She specializes in a personalized approach that blends genetics, epigenetics, biomarkers, and lifestyle factors to tailor health interventions that extend and optimize each patient's healthspan. Lauren's practice includes prescribing peptides (GLP, CLP/GIP) for weight loss, insulin resistance, pre-diabetes, etc.  This episode concentrates on MENOPAUSE. Lauren and Heather discuss what symptoms could be related to Menopause.  Lauren will speak about hot flashes, heart palpitations, frozen shoulder, brain fog, lack of libido, itchy ears, anxiety, trouble sleeping, hair changes, urinary tract infections. They will discuss what can you do at home and what treatments can be beneficial from professionals, such as GLP 1's for weight gain and  hormone replacement options.  Lauren is a frequent speaker at the Age Management Medicine Group (AMMG) and the American Academy of Anti-Aging Medicine (A4M) conferences.  Lauren's practice includes Cardiology prevention: Diagnostics and AI analysis to detect dangerous plaque and calcium; advanced lipid testing and cardiovascular genetics Longevity biomarkers: DNA methylation for biological age, VO2 max testing, Telomere health; Therapeutic plasma exchange Cancer prevention: methylated DNA screens, preventative MRIs, tumor marker testing.  Lauren's Website:     https://myventhealth.com/about/ Heather's Website: www.heatherthomson.com Social Media: IG: https://www.instagram.com/iamheathert/                     You Tube: https://youtube.com/@iamheathert?si=ZvI9l0bhLfTR-qdo SPONSORS:  BLISSY: Blissy is offering 60-nights risk-free PLUS an additional 30% off when you shop at www.Blissy.com/HEATHERPOD and use code HEATHERPOD. Your hair and skin will thank you! AIRDOCTOR: Go to AirDoctorPro.com and use promo code HEATHER to get UP TO $300 off today! AirDoctor comes with a 30-day money back guarantee, plus a 3-year warranty—an $84 value, free! Get this exclusive, podcast-only offer now at www.AirDoctorPro.com using promo code HEATHER. Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a textLast month, The Lancet posted online an article from Stine Johansen, Fredrik Åberg, Emmanuel Tsochatzis and Aleksander Krag, titled "Screening for Advanced Liver Disease." The article aims to update the Wilson and Jungner criteria, initially developed in 1960, to address modern needs and issues. In this conversation, Professor Krag and Dr. Johansen join Roger Green to discuss their article. There are many nuances and high points to cover in this thoughtful, fairly lengthy conversation, but one key point is that screening a mass population for HCC or cirrhosis has an entirely different set of issues and criteria compared to the screening usually discussed on this podcast, which involves identifying a population at increased risk for MASLD or MASH and screening them. Also, healthcare is far more expensive than it was in 1960 with a plethora of high-cost ways to diagnose, treat and manage patients.As a result, the authors started with the 10 Wilson and Jungner criteria and added eight more. During this conversation, Stine emphasizes the need for a comprehensive clinical trial on this issue, and all panelists agree that LiverAIM is likely to serve as the study.

Send us a textThis discussion on ways to improve MASH patient management comes from the early July roundtable on "Major Issues of the First Six Months of 2025." As a reminder, that roundtable included the three co-hosts (Louise, Jörn Schattenberg and Roger Green) Louise drives this conversation based on two related issues she sees emerging: (i) increasing opportunities for motivated patients to manage their own health and (ii) managing the total patient in an environment where people may be taking incretin agonists as if they are consumer drugs. With increased access to scanning, providers can monitor patients (and patients can self-monitor) more closely. However, some of the issues a provider might find are tricky: patients who undertake what Louise describes as "the sneaky areas patients think are normal, but are probably contributing to disease" due to miseducation or no education on healthy eating and lifestyle, or patients purchasing and using incretin agonists through consumer channels, but possibly at subtherapeutic doses. Vigilance and probing are key here, but health systems will need to train more people on the types of probing that uncover underlying issues and behaviors that patients mistakenly believe to be healthy. The discussion also extends to the role of NITs in diagnosis and patient management, and how providers need to shift the paradigm away from describing a patient by fibrosis stage and instead focus on the amount of fat in the liver and its overall suppleness.

Send us a textLet me begin by asking you: Have you ever sat in a dentist's chair, nervous, wishing the pain would end quickly? Now imagine instead of long drills and endless appointments, advanced robots and artificial intelligence tools handle procedures with incredible speed and accuracy. Sounds like a scene from a sci-fi movie, right? But let me tell you, this is already happening.Connect With Kapeel Guptaor Click on the link: http://bit.ly/4jlql8sWhat You May Learn00:00 Introduction02:05 Mission Statement02:25 #1: AI and Robotics Landscape in Modern Dentistry03:49 #2: AI powered Diagnostics & Personalised Treatment Planning05:06 #3: Robotics Automation in Clinical Procedures06:28 #4: Upskilling for the Future : Career Pathways & Training08:03 #5: Ethics, Regulation & Building Patient Trust09:20 Conclusion10:13 Call to actionSupport the show

Alexion recently launched the second film in its Rare Connections series, Rare Connections in gMG.Managing editor Jack O'Brien talks with Lucid Diagnostics' chief technology and compliance officer Dr. Brian deGuzman about the company's nationwide initiative to provide education and testing for esophageal precancer.He explains how the NFLPA factors into the effort, which launched in Cincinnati, and how it is expanding across the country to address the heightened risk these athletes have for developing esophageal pre-cancer.Check us out at: mmm-online.com  Fast Break theme music: Mark Buergler - On The Run, Triple Scoop Music Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, media trust, and data privacy—all under one roof. Don't wait—use promo code PODCAST for $100 off your individual ticket. Click here to register! AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket! Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music.

Send us a text00:00:00 - Surf's Up: Season 6 Episode 13 Louise Campbell, Jörn Schattenberg and Roger Green continue their discussion of some major issues from earlier this year, while co-authors Aleksander Krag and Stine Johanset join Roger to discuss their recent publication in The Lancet, titled "Screening for Advanced Liver Disease." 00:04:45 - Major Issues of the First Six Months: Integrated Patient ManagementLouise drives this conversation based on two related issues she sees emerging: (i) increasing opportunities for motivated patients to manage their own health and (ii) managing the total patient in an environment where people may be taking incretin agonists as if they are consumer drugs. With increased access to scanning, providers can monitor patients (and patients can self-monitor) more closely. However, some of the issues a provider might find are tricky: patients who undertake what Louise describes as "the sneaky areas patients think are normal, but are probably contributing to disease" due to miseducation or no education on healthy eating and lifestyle, or patients purchasing and using incretin agonists through consumer channels, but possibly at subtherapeutic doses. Vigilance and probing are key here, but health systems will need to train more people on the types of probing that uncover underlying issues and behaviors that patients mistakenly believe to be healthy. 00:21:02 - Newsmakers: Aleksander Krag and Stine Johansen discuss Screening for Advanced Liver DiseaseLast month, The Lancet posted online an article from Stine Johansen, Fredrik Åberg, Emmanuel Tsochatzis and Aleksander Krag, titled "Screening for Advanced Liver Disease." The article aims to update the Wilson and Jungner criteria, originally developed in 1960, to address modern needs and issues. In this conversation, Professor Krag and Dr. Johansen join Roger Green to discuss their article. There are many nuances and high points to cover in this thoughtful, fairly lengthy conversation, but the key point is that screening a mass population for HCC or cirrhosis has an entirely different set of issues and criteria compared to the screening usually discussed on this podcast, which involves identifying a population at increased risk for MASLD or MASH and screening them. 00:54:42 - Major Issues of the First Six Months: Changes in US Health Policy and Potential for Dynamism in the In-Office Scanning Market Roger drives this conversation, focusing on two very different, yet very important issues: the first is the increasing dynamism of the in-office scanning market, with leader Echosens developing new products and services, while companies like e-Scopics, Sonic Incytes, and Mindray (Hepatus) are introducing new devices with competing profiles. Roger discusses the idea that some scanners keep all data resident in the machine, while others send it immediately to the cloud. Louise suggests that we should welcome any reliable scanning device to the market. Separately, he lists some concerns about how the Trump Administration's focus on cutting services to the poor, coupled with Robert F. Kennedy Jr.'s distrust of pharmaceuticals and mainstream health research, might limit the number of Americans with access to healthcare and the kinds of care they can access. At the end of this conversation, Roger asks Jörn and Louise what they consider major issues for the next six months.01:11:40 - Business Report and Wrap-Up

This episode features Dr. Christopher Garcia, Chief Digital Innovation Officer at Mayo Clinic Laboratories, discussing how AI and big data are reshaping diagnostics. He shares insights on democratizing expertise, balancing innovation with patient safety, and creating trusted AI tools to advance healthcare.This episode is sponsored by Mayo Clinic Laboratories.

APMA in 2025 hosted "The National" at the Gaylord in Dallas, TX!   Dean's Chat, once again, went, "On Location"! This episode is sponsored by Bako Diagnostics, that graciously shared their booth with Dean's Chat! Dr. Johanna Richey interviewed many attendees discussing the scientific meeting, the networking, the collaboration and comaraderie withing the podiatric community.  Tune in for short interviews, this Part 2 episode consists of interviews on July 16, 2025.  Enjoy!  It was an incredible meeting for all!

We break down pneumothorax: risks, diagnosis, and management pearls. Hosts: Christopher Pham, MD Brian Gilberti, MD https://media.blubrry.com/coreem/content.blubrry.com/coreem/Pneumothorax.mp3 Download Leave a Comment Tags: Chest Trauma, Pulmonary, Trauma Show Notes Risk Factors for Pneumothorax Secondary pneumothorax Trauma: rib fractures, blunt chest trauma (as in the case). Iatrogenic: central line placement, thoracentesis, pleural procedures. Primary spontaneous pneumothorax Young, tall, thin males (10–30 years). Connective tissue disorders: Marfan, Ehlers-Danlos. Underlying lung disease: COPD with bullae, interstitial lung disease, CF, TB, malignancy. Technically, anyone is at risk. Symptoms & Differential Diagnosis Typical PTX presentation: Dyspnea, chest pain, pleuritic discomfort. Exam clues: unilateral decreased breath sounds, focal tenderness/crepitus. Red flags (suggest tension PTX): JVD Tracheal deviation Hypotension, shock physiology Severe tachycardia, hypoxia Differential diagnoses: Pulmonary: asthma, COPD, pneumonia, pulmonary edema (SCAPE), ILD, infections. Cardiac: ACS, CHF, pericarditis. PE and other acute causes of dyspnea. Diagnostics Bloodwork: limited role, except type & screen if intervention likely. EKG: reasonable given chest pain/shortness of breath.

Send us a textKey Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss  FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation focuses on benefits for patients and ways that having two drugs with different modes of action will change pharmacotherapy choices.This conversation starts with the group describing the sense of "enthusiasm" and "fulfillment" hepatology drug developers feel to see two drugs approved in the US and many other major changes to come (more drug approvals, FDA acceptance of a path to approval that is not based on liver biopsy). One interesting takeaway is that while the approval of semaglutide will likely change the number of patients treated with MASH pharmacotherapy, the greater impact of this approval will be on public awareness of MASH and the accompanying demand for treatment. In terms of actual drug use, the first major change will come among patients living with obesity but not Type 2 diabetes. Most of these patients previously saw their semaglutide prescriptions rejected for payment by health insurers. However, many of these patients will be living with MASH, and they are likely to see their prescriptions approved. Instead, the largest impact may involve increased education and awareness. Scott pointed out that endocrinologists, who frequently prescribe incretin agonists, will have reason to learn how to diagnose and manage MASH in patients they already treat. Zobair noted that an array of companies, starting with pharmaceutical manufacturers and scanning companies, will dramatically increase investments in prescriber and patient education. Another important benefit may come in terms of coverage. Scott points out that most patients living with obesity but not diabetes are unlikely to have their semaglutide prescriptions covered by commercial insurers. Those living with non-cirrhotic MASH are likely to have semaglutide covered. A separate but related point: Naim reports that ~30% of the MASH patients he sees are taking an incretin agonist at the time of initial visit.

APMA in 2025 hosted "The National" at the Gaylord in Dallas, TX!   Dean's Chat, once again, went, "On Location"!   This episode is sponsored by Bako Diagnostics, who graciously shared their booth with Dean's Chat! Dr. Johanna Richey interviewed many attendees discussing the scientific meeting, the networking, the collaboration and comaraderie withing the podiatric community.  Tune in for short interviews, Part 1 consists of interviews on July 15, 2025. Part 2, to be released next week, consists of interviews on July 16, 2025. Enjoy!  It was an incredible meeting for all!

Leviticus 16:15-19  1 John 1:5-2:6

In this episode of Medsider Radio, we sat down withTracy MacNeal, President and CEO of Materna Medical. Materna is developing two devices addressing different aspects of pelvic health: Ellora, aimed at preventing childbirth injuries during delivery, and Milli, designed to treat vaginismus, a pelvic floor condition that makes intercourse painful or impossible.Tracy is a healthcare executive and engineer with over 25 years of experience in medical devices, digital health, and women's health, including six successful transactions. In addition to heading Materna, Tracy serves on the AdvaMed Board and leads its Women's Health Equity Initiative, and was previously President of Diagnostics and Digital Health at Ximedica.In this interview, Tracy shares how clinical data enabled Materna to bridge B2B and B2C channels, and why clarity of focus is essential when commercialization paths diverge. Tracy also outlines what it takes to build in undefined markets, from aligning KOLs to publishing foundational definitions, and offers a candid perspective on what investors really want: clear financial returns, backed by a founder they trust to deliver when things go sideways.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Tracy MacNeal.

In this episode Ed Interviews Dr. Carrie Harmon of the University of Florida plant diagnostic center. They discuss plant diagnostics, how they have evolved over time and how the National Plant Diagnostic Network (NPDN) unites diagnosticians across the country. Additional Resources https://npdn.org/ https://apsjournals.apsnet.org/doi/full/10.1094/PHYTOFR-11-24-0123-FI https://pubmed.ncbi.nlm.nih.gov/34432509/ https://apsjournals.apsnet.org/doi/epdf/10.1094/PHP-08-20-0074-MR How to cite the podcast: Zaworski, E. (Host) Harmon, C. (Interviewee). S4:E29 (Podcast). Symp-tomb Check: Evolving Plant Disease Diagnostics. 8/13/25. In I See Dead Plants. Crop Protection Network. Transcript

In this episode of Skin Anarchy, host Dr. Ekta Yadav sits down with Irina Mazur, Chief Product and Marketing Officer at Revieve, to explore how AI is revolutionizing beauty—not just in products, but in personalized consumer experiences. With a background in mobile tech and digital health, Irina brings a deep understanding of how data can solve real-world problems—especially in an industry where personalization has become a buzzword.Revieve is building something different: a diagnostic platform that uses selfie-based analysis and hundreds of proprietary skin metrics to provide tailored skincare, makeup, and wellness recommendations—without collecting any personally identifiable data. But this isn't just about tech. It's about helping people understand the truth about their skin, bridging the gap between perception and clinical reality, and empowering consumers to make smarter, more confident choices.Irina shares how the company's approach to personalization goes far beyond basic filters. It adapts to the user, the brand, the category, and even the shopping environment. And for retailers, Revieve delivers serious impact: boosting conversions, increasing basket size, and even informing product development through anonymized insights.If you're curious about the future of diagnostics in beauty, the role of AI in lifestyle-based skincare, or how trust and transparency are redefining the industry, this conversation is a must-listen. Tune in to discover how Revieve is building the infrastructure for the next generation of intelligent, ethical, and personalizedTo learn more about Revieve, visit their website and social media.CHAPTERS:(0:00) Introduction to Irina Mazur and Revieve(1:05) Irina's Career Journey and Tech Influence in Beauty(2:46) The Evolution of Beauty and Consumer Interactions(4:00) Revieve's Comprehensive Consumer Journey(5:58) The Real Meaning of Personalization in Beauty(9:03) Skin Analysis Through AI and Consumer Perception(12:04) Educating Consumers on Their Skin Health(14:01) How Revieve Guides Product Recommendations(25:53) Wellness Integration into Beauty and Future Expansion(29:12) Closing Thoughts on the Future of Personalization in BeautyPlease fill out this survey to give us feedback on the show!Don't forget to subscribe to Skin Anarchy on Apple Podcasts, Spotify, or your preferred platform.Reach out to us through email with any questions.Sign up for our newsletter!Shop all our episodes and products mentioned through our ShopMy Shelf! Hosted on Acast. See acast.com/privacy for more information.